- Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
- Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
- Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
- Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
Dr Andrew Retter BSC, MBBS, MRCP, FRCPATH(HAEM), DICM
Chief Medical Officer
Andrew is Chief Medical Officer at Volition and an intensive care consultant in London.
Dr Andrew Retter serves as our Chief Medical Officer. Andrew is a United Kingdom-based consultant in critical care, ECMO and thrombosis with over 20 years of experience. He has been on the Specialist Register of the General Medical Council in Hematology and Intensive Care Medicine since 2014.
Andrew has been involved in clinical trials and research studies and has published over 50 articles in peer-reviewed medical journals. His areas of expertise include the management of hematological malignancies and the management of complex coagulopathies, anticoagulation, and sepsis. In addition to his clinical work, Dr Retter is also an accomplished educator and mentor. He teaches and trains medical students, residents, and fellows, and has served as a faculty member for educational courses. Andrew obtained his medical degree from St. George’s Hospital Medical School in 2001 and completed his postgraduate training in hematology and intensive care medicine at St. Thomas’ Hospital in London in 2013.
“In the healthcare profession, our goal is to detect disease early, rapidly treat patients and then be able to monitor treatment response. Volition’s pioneering technology has the potential to do just that, and to significantly improve patient outcomes.”
Andrew Retter BSC, MBBS, MRCP, FRCPATH(HAEM), DICM
Volition Chief Medical Officer